Zinc Finger Protein ZC3HAV1: Potential Drug Target Or Biomarker

Target Name: ZC3HAV1

NCBI ID: G56829

Zinc Finger Protein ZC3HAV1: Potential Drug Target Or Biomarker

Zinc finger CCCH-type antiviral protein 1 (ISOform 2) (ZC3HAV1) is a protein that is expressed in various tissues and cell types in the human body. It is characterized by the presence of a zinc finger domain and a CCCH-type repeats in its sequence. ZC3HAV1 has been shown to play a role in the immune response and has potential as a drug target or biomarker.

The zinc finger domain is a structural feature that is characterized by the presence of a zinc atom that is involved in a protein-protein interaction. This domain is found in a variety of proteins and is involved in the regulation of various cellular processes, including cell signaling, DNA replication, and stress response.

The CCCH-type repeats are a type of repetitive DNA sequence that is found in many proteins and is characterized by the presence of a specific pattern of nucleotides. CCCH-type repeats have been shown to play a role in the regulation of protein expression and have been implicated in a variety of diseases, including cancer.

ZC3HAV1 is a member of the Zinc finger gene family, which includes a variety of antiviral proteins that are involved in the regulation of viral infection. ZC3HAV1 is expressed in various tissues and cell types, including the brain, spleen, and immune cells, and has been shown to play a role in the immune response.

One of the key functions of ZC3HAV1 is its ability to interact with the immune response. ZC3HAV1 has been shown to play a role in the regulation of T cell function, including the development and activation of T cells. It has also been shown to interact with the protein PD-L1, which is involved in the regulation of immune responses and has been implicated in a variety of diseases, including cancer.

In addition to its role in the immune response, ZC3HAV1 has also been shown to play a role in the regulation of cellular processes that are important for cellular survival. For example, ZC3HAV1 has been shown to play a role in the regulation of cell cycle progression and has been shown to interact with the protein p21, which is involved in the regulation of cell growth and apoptosis.

Given its involvement in the immune response and its potential as a drug target, ZC3HAV1 is an attractive candidate for further study. Researchers are currently working to develop ZC3HAV1-based therapies for a variety of diseases, including cancer, autoimmune diseases, and viral infections.

In conclusion, ZC3HAV1 is a protein that is characterized by the presence of a zinc finger domain and a CCCH-type repeat. It is expressed in various tissues and cell types and has been shown to play a role in the immune response and the regulation of cellular processes. Further research is needed to fully understand the functions of ZC3HAV1 and its potential as a drug target or biomarker.

Protein Name: Zinc Finger CCCH-type Containing, Antiviral 1

Functions: Antiviral protein which inhibits the replication of viruses by recruiting the cellular RNA degradation machineries to degrade the viral mRNAs. Binds to a ZAP-responsive element (ZRE) present in the target viral mRNA, recruits cellular poly(A)-specific ribonuclease PARN to remove the poly(A) tail, and the 3'-5' exoribonuclease complex exosome to degrade the RNA body from the 3'-end. It also recruits the decapping complex DCP1-DCP2 through RNA helicase p72 (DDX17) to remove the cap structure of the viral mRNA to initiate its degradation from the 5'-end. Its target viruses belong to families which include retroviridae: human immunodeficiency virus type 1 (HIV-1), moloney and murine leukemia virus (MoMLV) and xenotropic MuLV-related virus (XMRV), filoviridae: ebola virus (EBOV) and marburg virus (MARV), togaviridae: sindbis virus (SINV) and Ross river virus (RRV). Specifically targets the multiply spliced but not unspliced or singly spliced HIV-1 mRNAs for degradation. Isoform 1 is a more potent viral inhibitor than isoform 2. Isoform 2 acts as a positive regulator of RIGI signaling resulting in activation of the downstream effector IRF3 leading to the expression of type I IFNs and IFN stimulated genes (ISGs)

More Common Targets